Richard Pops - Alkermes Plc Chairman and CEO
| ALKS Stock | USD 31.56 0.31 0.99% |
Chairman
Mr. Richard F. Pops is Chairman of the Board, Chief Executive Officer of the Company. Prior to assuming his current positions, Mr. Pops served as Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007 and as Chief Executive Officer and President from September 2009 until September 2011. Mr. Pops serves on the board of directors of Neurocrine Biosciences, Inc., Acceleron Pharma, Inc. and Epizyme Inc., all of which are publicly traded biotechnology companies. Mr. Pops also serves on the board of directors of the Biotechnology Innovation Organization, PhRMA and the National Health Council. He has previously served on the board of directors of two other publicly traded biopharmaceutical companies, Sirtris Pharmaceuticals from 2004 to 2008, and CombinatoRx, Incorporated from 2001 to 2009. Mr. Pops also served on the board of directors of Reliant Pharmaceuticals, a privately held pharmaceutical company purchased by GlaxoSmithKline in 2007, and on the advisory board of Polaris Venture Partners. He was a member of the Harvard Medical School Board of Fellows through June 2012. Mr. Pops is also on the advisory board for the Addiction Policy Forum. since 2011.
| Age | 63 |
| Tenure | 14 years |
| Address | Connaught House, Dublin, Ireland, D04 C5Y6 |
| Phone | 353 1 772 8000 |
| Web | https://www.alkermes.com |
Richard Pops Latest Insider Activity
Tracking and analyzing the buying and selling activities of Richard Pops against Alkermes Plc stock is an integral part of due diligence when investing in Alkermes Plc. Richard Pops insider activity provides valuable insight into whether Alkermes Plc is net buyers or sellers over its current business cycle. Note, Alkermes Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Alkermes Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Richard Pops over six months ago Acquisition by Richard Pops of 1700 shares of Neurocrine Biosciences at 42.76 subject to Rule 16b-3 | ||
Richard Pops over six months ago Acquisition by Richard Pops of 274328 shares of Alkermes Plc at 30.04 subject to Rule 16b-3 |
Alkermes Plc Management Efficiency
The company has return on total asset (ROA) of 0.0898 % which means that it generated a profit of $0.0898 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2923 %, meaning that it created $0.2923 on every $100 dollars invested by stockholders. Alkermes Plc's management efficiency ratios could be used to measure how well Alkermes Plc manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Alkermes Plc's Return On Capital Employed is comparatively stable compared to the past year. Return On Assets is likely to gain to 0.16 in 2025, whereas Return On Tangible Assets are likely to drop 0.16 in 2025. At this time, Alkermes Plc's Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 10.9 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Jack Bendheim | Phibro Animal Health | 78 | |
| Satish Reddy | Dr Reddys Laboratories | 52 | |
| Ronald CPA | Prestige Brand Holdings | 61 | |
| Ronald Lombardi | Prestige Brand Holdings | 60 | |
| David Stack | Pacira BioSciences, | 75 | |
| Sharon Mates | Intracellular Th | 72 | |
| RPh Pharm | Collegium Pharmaceutical | 61 | |
| G Prasad | Dr Reddys Laboratories | 59 | |
Management Performance
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.0898 |
Alkermes Plc Leadership Team
Elected by the shareholders, the Alkermes Plc's board of directors comprises two types of representatives: Alkermes Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alkermes. The board's role is to monitor Alkermes Plc's management team and ensure that shareholders' interests are well served. Alkermes Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alkermes Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Norman, Senior Relations | ||
| David Gaffin, Senior Vice President Chief Legal Officer | ||
| Richard Pops, Chairman and CEO | ||
| Iain Brown, Chief Accounting Officer | ||
| Blair Jackson, Executive Officer | ||
| Declan OConnor, Health Environment | ||
| Samuel Parisi, Interim Finance | ||
| Stephen Schiavo, Senior Resources | ||
| Michael Landine, Senior Vice President - Corporate Development | ||
| Thomas Harvey, Chief IT | ||
| Craig MD, Executive Officer | ||
| Floyd MD, Founder | ||
| David JD, Chief VP | ||
| Sandra Coombs, Senior Relations |
Alkermes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alkermes Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.0898 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 4.56 B | ||||
| Shares Outstanding | 161.8 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 98.70 % | ||||
| Number Of Shares Shorted | 11.37 M | ||||
| Price To Earning | (38.45) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alkermes Stock Analysis
When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.